We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Measuring what matters: advancing diversity, equity, and inclusion in lab medicine

By Jen A. Miller
Posted on 30 Jun 2026

Clinical laboratories play a key role in diagnosing and treating diseases and making meaningful contributions to patient outcomes. More...

But lab professionals can only provide equitable care if they understand how care varies across different demographics. Laboratories are best positioned to meet this need when they foster diversity, equity, and inclusion (DEI) among both their workforce and the patients they serve. In short, a laboratory workforce that is representative of the patient population it serves translates to better care.

At ADLM 2026, Jaime Noguez, PhD, DABCC, will moderate a scientific session on July 27 that explores how labs can meaningfully advance DEI efforts. Noguez, who is director of clinical chemistry and toxicology at University Hospitals Cleveland Medical Center and associate professor of pathology at Case Western Reserve University, said that achieving these goals requires far more than simply recognizing their importance.

“Laboratorians are often told why DEI matters, but rarely are we given guidance on how to operationalize those concepts in the laboratory environment,” said Noguez. “Our goal is to help laboratories move from simply having good intentions for DEI to actually having measurable action.”

The session, titled “Measuring what matters: a practical framework for advancing diversity, equity, and inclusion in lab medicine,” also features speakers Zahra Shajani-Yi, PhD, DABCC, FADLM, NRCC, voluntary associate clinical professor in the department of pathology at the University of California, San Diego, and Sean Campbell, PhD, DABCC, FADLM, adjunct associate professor in the department of pathology at the Albert Einstein College of Medicine and clinical biochemist at Sinai Health System.

Noguez, Shajani-Yi, and Campbell all serve on ADLM’s DEI Steering Committee. Together, they will present practical, evidence-based strategies for assessing and strengthening DEI efforts in clinical laboratory settings. Attendees will explore common barriers to achieving DEI, review real-world examples of successful initiatives, and learn how to apply a customizable scorecard to evaluate their own organizations and foster a community of inclusion and belonging.

The session will focus on three key areas. First, the speakers will introduce meaningful DEI metrics that clinical laboratories can use to guide decision-making and track progress. The name of the session is intentional in that way. “When we chose the phrase [“Measuring what matters”] for our title, in this context it means looking at meaningful indicators rather than simply counting DEI-related activities,” Noguez said. 

Next, the presenters will address DEI among clinical laboratory workers. “We face significant workforce shortages and are trying to attract more individuals to a career in laboratory medicine. Creating an inclusive environment is essential not only for recruitment but also for long-term retention,” Noguez said.

Finally, the speakers will talk about DEI-related patient care gaps and share examples of successful efforts to fill them. 

Designed as an interactive experience rather than a traditional lecture, this session will integrate audience polling and scenario-based discussions that panelists and attendees will participate in together. “We’re allowing participants to apply concepts we’re talking about in real time and learn from peers facing similar challenges,” said Noguez. 

The session is for people in various roles across the clinical laboratory, including leaders, pathologists, and front-line laboratorians. “It is intended for anyone who wants to strengthen organizational culture while also improving patient care,” Noguez said.

Overall, instead of just talking about DEI as an abstract concept, the speakers aim to inspire action. “We want to help clinical laboratorians understand how DEI efforts tie directly to metrics and connect metrics to tangible improvements in patient care,” Noguez said.


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.